Surveillance of linezolid resistance in Germany, 2001-2002

Clinical Microbiology and Infection

Volumn 11, Issue 1, 2005, Pages 39-46

  Brauers, Johannes ^a   Kresken, M ^a   Hafner, D ^b   Shah, P M ^c  

^a Antiinfectives Intelligence GmbH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antibiotic resistance; Enterococcus spp.; Germany; Linezolid; Staphylococcus spp.; Streptococcus spp.

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN G; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ADULT; AGED; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CATHETER INFECTION; CONTROLLED STUDY; DIFFUSION; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; FEMALE; FOREIGN BODY; GERMANY; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; URINARY TRACT INFECTION;

ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; POSIBACTERIA; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 13644250305     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.01036.x     Document Type: Article

References (36)

1. Baquero, F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997; 39 suppl A): 1-6.
2. Cormican M, Jones R. Emerging resistance to antimicrobial agents in gram-positive bacteria: enterococci, staphylococci and non-pneumococcal streptococci. Drugs 1996; 51(suppl 1): 6-12.
3. Hiramatsu K, Aritaka N, Hanaki H et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-1673.
4. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR 2002; 51: 565-567.
5. Centers for Disease Control and Prevention. Public health dispatch: vancomycin-resistant Staphylococcus aureus - Pennsylvania, 2002. MMWR 2002; 51: 902.
6. Kloss P, Xiong L, Shinabarger D, Mankin A. Resistance mutations in 23S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center. J Mol Biol 1999; 294: 93-101.
7. Fines M, Leclercq R. Activity of linezolid against gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors. J Antimicrob Chemother 2000; 45: 797-802.
8. Henwood C, Livermore D, Johnson A, James D, Warner M, Gardiner A. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000; 46: 931-940.
9. Patel R, Rouse M, Piper K, Steckelberg J. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 1999; 34: 119-122.
10. Zurenko G, Yagi B, Schaadt R et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-845.
11. Gemmel C. Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison. J Antimicrob Chemother 2001; 48: 47-52.
12. Bolmstrom A, Ballow C, Qwarnstrom A, Biedenbach D, Jones R. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvoxy® antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect 2002; 8: 791-800.
13. Frédénucci I, Chomarat M, Bercion R et al. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae. Clin Microbiol Infect 2002; 8: 680-683.
14. Wilcox M. Efficacy of linezolid versus comparator therapies in gram-positive infections. J Antimicrob Chemother 2003; 51 suppl S2): 27-35.
15. Deutsches Institut für Normung (DIN), Normenausschuss Medizin (NAMed). Methoden zur Empfindlichkeitsprüfung von bakteriellen Krankheitserregern (außer Mykobakterien) gegen Chemotherapeutika. Mikrodilution. DIN 58940. Cologne: DIN, 1990.
16. Deutsches Institut für Normung (DIN), Normenausschuss Medizin (NAMed). Methoden zur Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika. Teil 4: Bewertungsstufen der minimalen Hemmkonzentration MHK-Grenzwerte von antibakteriellen Wirkstoffen. Beiblatt 1 zu DIN 58940-4. Cologne: DIN, 2000.
17. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests, 7th edn. Approved standard M2-A7, vol. 20, no. 1. Wayne, PA: NCCLS, 2000.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 12th informational supplement. M100-S12, vol. 22, no. 1. Wayne, PA: NCCLS, 2002.
19. Rosenthal E. Epidemiologie von Septikämie-Erregern. Deutsche Med Wochenschr 2002; 127: 2435-2440.
20. Reinert R, Al-Lahham A, Lemperle M et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002; 49: 61-68.
21. Deutsches Institut für Normung (DIN), Normenausschuss Medizin (NAMed). Methoden zur Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika. Teil 3: Agardiffusionstest. Angaben für die Bewertung der Hemmhofdurchmesser DIN 58940-3. Cologne: DIN, 2000.
22. Tenover FC, Lancaster MV, Hill BC et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36 1020-1027.
23. Fitch I, Johnson AP. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of Staphylococcus aureus. J Antimicrob Chemother 1998; 41: 578.
24. Andrews JM, the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 3). J Antimicrob Chemother 2004, 53: 713-718.
25. Henwood CJ, Livermore DM, Johnson AP et al. Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000; 46: 931-940.
26. Mouton JW, Jansz AR. The DUEL study: a multi-center in vitro evaluation of linezolid compared with other antibiotics in the Netherlands. Clin Microbiol Infect 2001; 7: 486-491.
27. Szczypa K, Betlejewska K, Nowak K et al. In vitro activity of linezolid against gram-positive cocci isolated in Poland. J Antimicrob Chemother 2001; 48: 932-935.
28. Stefani S, Mezzatesta L, Tempera G et al. Comparative activity of linezolid against staphylococci and enterococci isolated in Italy. Clin Microbiol Infect 2002; 8: 368-372.
29. Ballow CH, Jones RN, Biedenbach DJ et al. A multicenter evaluation of linezolid antimicrobial activity in North America. Diagn Microbiol Infect Dis 2002; 43: 75-83.
30. Bolmstrom A, Ballow CH, Qwarnstrom A et al. Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvoxy® antimicrobial potency study (ZAPS-Europe). Clin Microbiol Infect 2002; 8: 791-800.
31. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA, für die Studiengruppe: Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. aus dem Jahre 2001. Bonn: Antiinfectives Intelligence, 2003.
32. Korn S, Shah P. In-vitro-Aktivität von Linezolid gegen Staphylococcus species im Vergleich zu anderen Antibiotika. Chemother J 2002; 11: 87-89.
33. Von Eiff C, Peters G. Comparative in-vitro-activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 1999; 43: 569-573.
34. Zurenko G, Todd W, Hafkin B et al. Development of linezolid-resistant Enterococcus faecium in two compassionate use program patients treated with linezolid [abstract 848]. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1999; 118.
35. Tsiodras S, Gold S, Sakoulas G et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-208.
36. Wilson P, Andrews J, Charlesworth R et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 186-188.